Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 07/31
| 07-2020 | 07-2019 | 07-2018 | 07-2017 | 07-2016 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 211 | 125 | 165 | 130 | 134 |
| Accounts receivable | 61 | 25 | 315 | -141 | 2 |
| Accounts payable and accrued liabilities | -1,545 | 1,048 | 554 | 723 | 453 |
| Other Working Capital | -2,111 | 1,473 | 866 | 676 | 431 |
| Other Operating Activity | -7,442 | -8,202 | -9,424 | -10,683 | -9,873 |
| Operating Cash Flow | $-10,826 | $-5,531 | $-7,524 | $-9,295 | $-8,853 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -16 | -4 | -53 | -214 | -40 |
| Net Acquisitions | 1,720 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $1,704 | $-4 | $-53 | $-214 | $-40 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -151 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 12,185 | 5,411 | 7,105 | 6,499 | 5,445 |
| Other Financing Activity | 1,062 | 0 | 0 | 220 | 327 |
| Financing Cash Flow | $13,096 | $5,411 | $7,105 | $6,719 | $5,772 |
| Exchange Rate Effect | 55 | -36 | -59 | 33 | -17 |
| Beginning Cash Position | 206 | 366 | 897 | 3,654 | 6,792 |
| End Cash Position | 4,235 | 206 | 366 | 897 | 3,654 |
| Net Cash Flow | $3,974 | $-124 | $-472 | $-2,790 | $-3,121 |
| Free Cash Flow | |||||
| Operating Cash Flow | -10,826 | -5,531 | -7,524 | -9,295 | -8,853 |
| Capital Expenditure | -16 | -4 | -53 | -382 | -40 |
| Free Cash Flow | -10,842 | -5,535 | -7,577 | -9,677 | -8,893 |